Division of MDxHealth SA
Latest From NovioGendix
Cancer diagnostics company MDxHealth is poised for more commercial growth in 2018 following a move to larger lab facilities in Nijmegen, the Netherlands. The move is part of the company's strategy to grow commercialization of its SelectMDx prostate cancer test in Europe and conduct additional R&D activities.
AstraZeneca offloaded former Amgen-partnered IL-17 antagonist brodalumab to Valeant; there was consolidation in the dental instruments industry via the $5.3bn merger of Dentsply and Sirona. Compared with August, financing in the biopharma sector was up while device was flat.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical Tools – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2015.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced August-September 2015.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Urine-based Testing
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- MDxHealth SA
- Senior Management
Willem Melchers, PhD, CEO
Jack Schalken, PhD, CSO
- Contact Info
Phone: 24 327 94 94
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.